NYSE:BHC Bausch Health Companies (BHC) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free BHC Stock Alerts $8.51 -0.02 (-0.23%) (As of 01:32 PM ET) Add Compare Share Share Today's Range$8.45▼$8.5950-Day Range$8.41▼$10.6152-Week Range$5.57▼$11.46Volume521,853 shsAverage Volume2.77 million shsMarket Capitalization$3.11 billionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Bausch Health Companies alerts: Email Address Bausch Health Companies MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside46.9% Upside$12.50 Price TargetShort InterestHealthy6.31% of Float Sold ShortDividend StrengthN/ASustainability-1.42Upright™ Environmental ScoreNews Sentiment0.68Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth3.04%From $3.95 to $4.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.00 out of 5 starsMedical Sector156th out of 909 stocksPharmaceutical Preparations Industry59th out of 423 stocks 3.2 Analyst's Opinion Consensus RatingBausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBausch Health Companies has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.31% of the float of Bausch Health Companies has been sold short.Short Interest Ratio / Days to CoverBausch Health Companies has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Bausch Health Companies has recently decreased by 5.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBausch Health Companies does not currently pay a dividend.Dividend GrowthBausch Health Companies does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBausch Health Companies has received a 55.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Allergy eye drops", "Anti-diarrheal and intestinal anti-inflammatory medication (A07)", "Laxatives", and "Intraocular lenses" products. See details.Environmental SustainabilityThe Environmental Impact score for Bausch Health Companies is -1.42. Previous Next 3.2 News and Social Media Coverage News SentimentBausch Health Companies has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Bausch Health Companies this week, compared to 4 articles on an average week.Search Interest41 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Bausch Health Companies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch Health Companies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.12% of the stock of Bausch Health Companies is held by insiders.Percentage Held by Institutions78.65% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bausch Health Companies are expected to grow by 3.04% in the coming year, from $3.95 to $4.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bausch Health Companies is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bausch Health Companies is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Bausch Health Companies Stock (NYSE:BHC)Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Read More BHC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHC Stock News HeadlinesApril 24, 2024 | americanbankingnews.comBausch Health Companies (NYSE:BHC) Price Target Lowered to $11.00 at Royal Bank of CanadaApril 16, 2024 | americanbankingnews.comShort Interest in Bausch Health Companies Inc. (NYSE:BHC) Declines By 5.4%April 24, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”April 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Walgreens Boots Alliance (WBA) and Evolent Health (EVH)April 14, 2024 | americanbankingnews.comBausch Health Companies' (BHC) Sector Perform Rating Reaffirmed at Royal Bank of CanadaApril 11, 2024 | reuters.comBausch wins US appeal to block Alvogen generic of diarrhea drugApril 9, 2024 | theglobeandmail.comClosing Bell: Bausch Health Companies Inc down on Monday (BHC)April 8, 2024 | msn.comBausch Health (NYSE:BHC) Falls 7% amid New Legal IssuesApril 24, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”April 6, 2024 | msn.comBausch Health sues Amneal Pharma over Xifaxan genericApril 5, 2024 | finanznachrichten.deBausch Health Companies Inc.: Bausch Health Announces Patent Lawsuit Against Amneal PharmaceuticalsApril 2, 2024 | finance.yahoo.comBased on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider ConversationsMarch 30, 2024 | theglobeandmail.comBausch Health Companies: Stocks Overvalued by Analyst Consensus on TSX (BHC)March 28, 2024 | insidermonkey.comThe Enduring Losses Incurred by Carl Icahn’s 10 Activist Targets over the Long TermMarch 28, 2024 | msn.comThis Bausch Health Companies Unusually Active Option Is a No-BrainerMarch 27, 2024 | businesswire.comBausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual MeetingMarch 16, 2024 | finance.yahoo.comBHC Mar 2024 9.000 callMarch 16, 2024 | finance.yahoo.comBHC Mar 2024 9.000 putMarch 11, 2024 | finance.yahoo.comBHC Mar 2024 5.500 callMarch 6, 2024 | finance.yahoo.comBausch Health Companies Inc. (BHC)March 6, 2024 | finanznachrichten.deSalix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell CarcinomaFebruary 28, 2024 | businesswire.comBausch + Lomb Announces Appointment of Karen L. Ling to Board of DirectorsFebruary 24, 2024 | seekingalpha.comBausch Health: A Timely Divestiture Is The Key To An Higher ValuationFebruary 22, 2024 | marketwatch.comBausch Health 4Q Loss Narrows, Revenue Growth Tops AnalystsFebruary 21, 2024 | msn.comBausch + Lomb Offers Upbeat 2024 Revenue Outlook as Fourth-Quarter Results Exceed ViewsFebruary 21, 2024 | msn.comBausch Health Companies Q4 2023 Earnings PreviewFebruary 21, 2024 | finance.yahoo.comCompared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key MetricsSee More Headlines Receive BHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/24/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:BHC CUSIPN/A CIK885590 Webwww.bauschhealth.com Phone(514) 744-6792Fax514-744-6272Employees20,270Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$14.00 Low Stock Price Target$11.00 Potential Upside/Downside+46.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.62) Trailing P/E RatioN/A Forward P/E Ratio2.16 P/E GrowthN/ANet Income$-592,000,000.00 Net Margins-6.76% Pretax Margin-4.45% Return on Equity5,147.48% Return on Assets4.84% Debt Debt-to-Equity RatioN/A Current Ratio1.30 Quick Ratio0.94 Sales & Book Value Annual Sales$8.76 billion Price / Sales0.36 Cash Flow$7.29 per share Price / Cash Flow1.17 Book Value($0.23) per share Price / Book-37.09Miscellaneous Outstanding Shares365,410,000Free Float335,741,000Market Cap$3.12 billion OptionableOptionable Beta0.85 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Thomas J. Appio (Age 62)CEO & Director Comp: $2.74MMr. John S. Barresi (Age 51)Senior VP, Controller, Chief Accounting Officer & Interim CFO Comp: $796.8kMs. Seana Carson (Age 51)Executive VP & General Counsel Comp: $872.65kMr. Mirza DautbegovicSenior VP & COOMr. Josh CoyleSenior Vice President of Sales & SalixMs. Kathleen FitzpatrickSenior VP & Chief HR OfficerDr. Tage Ramakrishna M.D. (Age 50)Chief Medical Officer and President of R&D Mr. Jeff HartnessExecutive VP of Market Access, Commercial Operations, Neurology, Generics & Government AffairsDr. Graham JacksonSenior VP & Chief Quality OfficerMr. Cees HeimanSenior Vice President of Europe & CanadaMore ExecutivesKey CompetitorsXenon PharmaceuticalsNASDAQ:XENECrinetics PharmaceuticalsNASDAQ:CRNXAmicus TherapeuticsNASDAQ:FOLDHUTCHMEDNASDAQ:HCMBiohavenNYSE:BHVNView All CompetitorsInsiders & InstitutionsFinancial Sense Advisors Inc.Sold 4,150 shares on 4/19/2024Ownership: 0.030%Thompson Investment Management Inc.Sold 7,966 shares on 4/15/2024Ownership: 0.058%IMC Chicago LLCBought 179,100 shares on 4/13/2024Ownership: 0.000%Range Financial Group LLCBought 7,514 shares on 4/12/2024Ownership: 0.024%Salem Investment Counselors Inc.Bought 2,975 shares on 4/11/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions BHC Stock Analysis - Frequently Asked Questions Should I buy or sell Bausch Health Companies stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares. View BHC analyst ratings or view top-rated stocks. What is Bausch Health Companies' stock price target for 2024? 3 brokers have issued 12-month target prices for Bausch Health Companies' stock. Their BHC share price targets range from $11.00 to $14.00. On average, they predict the company's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price. View analysts price targets for BHC or view top-rated stocks among Wall Street analysts. How have BHC shares performed in 2024? Bausch Health Companies' stock was trading at $8.02 at the beginning of the year. Since then, BHC shares have increased by 6.1% and is now trading at $8.51. View the best growth stocks for 2024 here. Are investors shorting Bausch Health Companies? Bausch Health Companies saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 22,500,000 shares, a decrease of 5.4% from the March 15th total of 23,780,000 shares. Based on an average daily trading volume, of 2,640,000 shares, the short-interest ratio is presently 8.5 days. Approximately 6.3% of the company's stock are short sold. View Bausch Health Companies' Short Interest. When is Bausch Health Companies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BHC earnings forecast. How can I listen to Bausch Health Companies' earnings call? Bausch Health Companies will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Bausch Health Companies' earnings last quarter? Bausch Health Companies Inc. (NYSE:BHC) issued its earnings results on Thursday, February, 22nd. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.01 by $0.14. The business had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive trailing twelve-month return on equity of 5,147.48%. The business's revenue was up 9.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.02 earnings per share. What ETFs hold Bausch Health Companies' stock? ETFs with the largest weight of Bausch Health Companies (NYSE:BHC) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV).VanEck Pharmaceutical ETF (PPH). What guidance has Bausch Health Companies issued on next quarter's earnings? Bausch Health Companies issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.3 billion-$9.3 billion, compared to the consensus revenue estimate of $9.0 billion. What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO? 43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Bausch Health Companies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC). Who are Bausch Health Companies' major shareholders? Bausch Health Companies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Thompson Investment Management Inc. (0.06%), IMC Chicago LLC (0.00%), Financial Sense Advisors Inc. (0.03%), Range Financial Group LLC (0.02%), Marotta Asset Management (0.00%) and Salem Investment Counselors Inc. (0.00%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson and Steven D Miller. View institutional ownership trends. How do I buy shares of Bausch Health Companies? Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:BHC) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch Health Companies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
